- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
335
nonBactErial infEctions of tHE gEnitoUrinary tract
definitive, but insensitive.10 A variety of immu- |
transmitted by the Simulium ssp blackflies. |
|
noassays are available including ELISA, the ICT |
Infected larvae are deposited in the subcutane- |
|
filarial antigen test, antifilarial IgG4 antibody |
ous tissue and mature to adult worms within a |
|
levels, filarial acetylcholinesterase levels, and |
year, causing subcutaneous nodules. Throughout |
|
PCR51 Choice of methodology will likely be dic- |
their 14-year lifespan, the worms release microfi- |
|
tated by which resources are available to the |
larias, which cause a host inflammatory reaction |
|
diagnosing physician. Finally, suspected filarial |
that leads to the clinical manifestations of chronic |
|
diagnosis can be confirmed by ultrasound |
dermatitis, skin atrophy, ocular inflammation |
|
which demonstrates the “filarial dance sign” |
and blindness, and inguinal lymphadenitis, and |
|
with visualization of motile scrotal worms. This |
scrotal elephantiasis.60,61 While both filarial dis- |
|
may be seen even in otherwise asymptomatic |
eases may present with elephantiasis and lym- |
|
individuals.54 |
phedema,the distinction between onchocerciasis |
|
|
and lymphatic filariasis is important as dieth- |
|
|
ylcarbamazine (Table 24.2), a mainstay of |
|
Treatment |
treatment for lymphatic filariasis, causes the |
|
|
Mazzotti reaction in onchocerciasis. This reac- |
|
On an individual level, chemotherapy is the |
tion is caused by a severe immune reaction to |
|
mainstay of treatment (Table 24.2).Several treat- |
dead or dying worms characterized by fever, |
|
ment regimens are currently utilized, but cur- |
hypotension, tachycardia, adenitis, arthralgia, |
|
rently a single dose of albendazole in combination |
and pruritis.62 Thus, Ivermectin is the primary |
|
with either diethylcarbamazine or ivermectin |
chemotherapeutic agent used to treat onchocer- |
|
are effective at eradicating microfilaremia.51,55 |
ciasis, and requires yearly treatments to main- |
|
Patients must be counseled regarding significant |
tain amicrofilaridermia. New studies have |
|
side effects with the use of diethylcarbamazine |
elucidated the role of endosymbiotic bacteria in |
|
such as fevers, arthralgias, headache, nausea, |
the primary pathogenesis of, and severe treat- |
|
and vomiting. This is related to worm death and |
ment reactions of onchocerciasis. Wolbachia is a |
|
will be more severe in patients with large worm |
Rickettsia-like bacteria found in the hypoder- |
|
burdens.52 In addition to standard chemother- |
mis, oocytes, and microfilaria of O. Volvulus and |
|
apy regimens, recent study has used concurrent |
appears essential to the fertility of the nema- |
|
regimens of doxycycline to target endosymbi- |
tode. In addition, they have endotoxin-like |
|
ants such as Wolbachia believed be essential to |
effects that are thought to be one of the pri- |
|
worm fertility.56 |
mary mechanisms behind the immunologic |
|
In addition to chemotherapy, the sequelae of |
response behind the nematode’s clinical mani- |
|
filariasis such as lymphedema and elephantiasis |
festations. In patients treated with doxycycline |
|
can be reduced with the use of improved hygiene |
to eradicate Wolbachia, the absence of microfi- |
|
and antibacterial soaps,57 as well as treatment of |
laridermia was persistent at 18 months, in con- |
|
lymphatic and scrotal superinfections believed |
trast to ivermectin alone which allows the |
|
to be a major contributor to chronic filariasis.58 |
resurgence of microfilaridermia at as early as 4 |
|
Retrograde lymphangiography may be diagnos- |
months.63 These findings may be the beginning |
|
tic and therapeutic. While demonstrating the |
of new treatment algorithms and a new under- |
|
severe lymphatic obstruction,the contrast mate- |
standing of filarial pathogenesis. |
|
rial can sclerose lymphatic fistulas in nearly half |
|
|
of patients.59 Surgical treatment of filariasis is |
References |
|
aimed mainly at correcting the anatomic seque- |
||
|
||
lae of filariasis by hydrocele repair or genital |
|
|
reconstruction. |
1. Kauffman CA, Vazquez J, Sobel J, et al. Prospective mul- |
|
|
ticenter surveillance study of funguria in hospitalized |
|
Onchocerciasis |
patients. Clin Infect Dis. 2000;30:14-18 |
|
2. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and |
||
|
||
|
attributable outcomes of candidemia in adults and chil- |
|
Onchocerciasis is a filarial disease caused by |
dren hospitalized in the United States: a propensity |
|
analysis. Clin Infect Dis. 2005;41:1232-1239 |
||
Onchocerca volvulus. Also known as “African |
||
3. Hamory BH, Wenzel RP. Hospital associated candiduria: |
||
River blindness,” it affects 17 million people in |
predisposing factors and review of the literature. J Urol. |
|
areas of Africa, Latin America, and Yemen. It is |
1978;120:444-448 |
336
Practical Urology: EssEntial PrinciPlEs and PracticE
4.Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643
5.Wise GJ, Talluri GS, Marella VK. Fungal infections of the genitourinary system: manifestations, diagnosis, and treatment. Urol Clin N Am. 1999;26:701-718
6.Lentino JR, Zielinski A, Stachowski M, et al. Prostatic abscesses due to candida albicans. J Infect Dis. 1984;149:282
7.Docimo SG, Kang J, Rukstalis D, et al. Candida epididymitis: newly recognized opportunistic epididymal infection. Urology. 1993;41:280-282
8.Nassoura Z, Ivatury RR, Stahl WM, et al. Candiduria as an early marker of disseminated infection in critically ill surgical patients. The role of fluconazole therapy. J Trauma. 1994;35:290-295
9.Pappas PG. Invasive candidiasis. Infect Dis Clin N Am. 2006;20:485-506
10.McAleer SJ, Johnson CW, Johnson WD Jr. In: Wein AJ, Kavoussi LR, et al, editors. Tuberculosis and Parasitic and Fungal infections of the Genitourinary systems. CampbellWalsh Urology. 9th ed. Philadelphia, PA: W. B. Saunders; 2007. p. 436-470
11.Wise GJ, Silver D. Fungal infections of the genitourinary system. J Urol. 1993;148:1377-1388
12.Young RC, Bennett JR, Vogel CL, et al. Aspergillosis. The spectrum of disease in 98 patients. Medicine. 1970;49:147
13.Khan ZU, Gopalakrishnan G, Al-Awadi K, et al. Renal aspergilloma due to Aspergillus flavus. Clin Infect Dis. 1995;12:210-212
14.Bibler MR, Gianis JT. Acute ureteral colic from an obstructing renal aspergilloma. Rev Infect Dis. 1987;9:790-793
15.Shah B, Taylor HC, Pillay I, et al. Adrenal insufficiency due to cryptococcosis. JAMA. 1986;256:3247
16.Salyer WR, Salyer DC. Involvement of the kidney and prostate in cryptococcosis. J Urol. 1973;109:695
17.Larsen RA, Bozzette S, McCutchan JA, et al. Persistant
Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California collaborative treatment group. Ann Intern Med. 1989;111:125
18.Eickenberg HU, Amin M, Lich R Jr. Blastomycosis of the genitourinary tract. J Urol. 1975;113:650
19.Bergner DM, Kraus SD, Duck GB, et al. Systemic blastomycosis presenting with acute prostatic abscess. J Urol. 1981;126:132
20.Craig MW, Davey WN, Green RA. Conjugal blastomycosis. Am Rev Respir Dis. 1970;102:86
21.Kuntze JR, Herman MH, Evans SG. Genitourinary coccidioidomycosis. J Urol. 1988;140:370
22.Conner WT, Drach GW, Bucher WC Jr. Genitourinary aspects of disseminated coccicioidomycosis. J Urol. 1975;113:82
23.Price MJ, Lewis EL, Carmalt JE. Coccidioidomycosis of the prostate gland. Urology. 1982;19:653
24.Einstein HE, Johnson RH. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis. 1993;16:349-354
25. Sohail MR, Andrews PE, Blair J. Coccicioidomycosis of the male genital tract. J Urol. 2005;173: 1978-1982
26.Goodwin RA Jr, Shapiro JL, Thurman GH, et al. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine. 1980;59:1
27.Rubin H, Furclow ML, Yates JL, et al. The course and prognosis of histoplasmosis. Am J Med. 1959;27:278
28.Wilson DA, Muchmore GH, Tisdal RG, et al. Histoplasmosis of the adrenal gland studied by CT. Radiology. 1984;150:779
29.Bartlett JG, John Hopkins antibiotic guide. http://prod. hopkins-abxguide.org/. Accessed March 9, 2009
30.Wise GJ, Marella V. Genitourinary manifestations of tuberculosis. Urol Clin N Am. 2003;30(1):111-121
31.Weinberg AC, Boyd SD. Short-course chemotherapy and the role of surgery in adult and pediatric genitourinary tuberculosis. Urology. 1988;31:95
32.Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200
33.Wise GJ, Shyteynshlyuger A.An update on lower urinary tract tuberculosis. Curr Prostatic Rep. 2007;5:87-95
34.Gow JG. The current management of patients with genitourinary tuberculosis. AUA Update Ser. 1992;26: 202-207
35.Carl P, Stark L. Indications for surgical management of genitourinary tuberculosis. World J Surg. 1997;21: 505-510
36.Premkumar A, Lattimer J, Newhouse JH. CT and sonography of advanced urinary tract tuberculosis. Am J Rad. 1987;148:65-69
37.Vijaikumar M, Thappa DM, Kaviarasan PK. Papulonecrotic tuberculide of the glans penis. Sex Transm Infect. 2001;77:147
38.Pal DK. Erectile failure and destruction of glans penis by tuberculosis. Trop Doct. 1997;27:178
39.Wolf JS Jr, McAninch JW. Tuberculous epididymo-orchi- tis: diagnosis by fine needle aspiration. J Urol. 1991;145:836-838
40.Koukol SC, DeHaven JI, Riggs DR, et al. Drug therapy of bacillus Calmette-Guerin sepsis. Urol Res. 1995;22: 373376
41.Wang LJ,Wong YC, Chen CJ, Lim KE. CT features of genitourinary tuberculosis. J Comput Assist Tomogr. 1997;21:254-258
42.Chung JJ, Kim MJ, Lee T, et al. Sonographic findings in tuberculosis epididymitis and epididymo-orchitis. J Clin Ultrasound. 1997;25:390-394
43.Fraietta R, Mori MM, De Oliveira JM, et al. Tuberculosis of seminal vesicles as a cause of aspermia. J Urol. 2003;169:1472
44.Sheehan G, Sekla L, Harding GKM. Urinary schistosomiasis: a report of four cases and a review. Can Med Assoc J. 1984;131:1361-1364
45.Cheever A, Kuntz RE, Moore J, et al. Carcinoma of the urinary bladder in Schistosoma haematobium infection. Am J Path. 1976;84:673-676
46.Smith MD, Verroust PJ, Morel-Maroger L, et al. A study of the presence of circulating immune complexes in schistosomiasis. Trans R Soc Trop Med Hyg. 1977;71: 343-348
337
nonBactErial infEctions of tHE gEnitoUrinary tract
47.Smith JH, Kamel IA, Elwi A, et al. A quantitative post mortem analysis of urinary schistosomiasis in Egypt. Pathology and pathogenesis. Am J Trop Med Hyg. 1974;23:1054-1071
48.Tsang VC, Wilkins PP. Innumodiagnosis of schistosomiasis. Immunol Invest. 1997;26:175-188
49.Jorulf H, Lindstedt E. Urogenital schistosomiasis: CT evaluation. Radiology. 1985;157:745-749
50.Michael E, Bundy D. Global mapping of lymphatic filariasis. Parasitol Today. 1997;13:472-476
51.Melrose WD. Lymphatic filariasis: new insights into an old disease. Int J Parasitol. 2002;32:947-960
52.Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF. Pathogenesis of lymphatic disease in bancroftian filariaisis: A clinical perspective. Parasitol Today. 2000;16: 544-548
53.Iturregui-Pagan J, Fortuno R, Noy M. Genital manifestations of filariasis. Urology. 1976;8:207-209
54.Noroes J,Addiss D, Santos A, et al. Ultrasonic evidence of abnormal lymphatic vessels in young men with adult Wuchereria bancrofti infection in the scrotal area. J Urol. 1996;156:409-412
55.World Health Organization. Lymphatic filariasis. Fact sheet N 102. 2000. http://www.who.int/mediacentre/factsheets/fs102/en/. Accessed December 7, 2008
56.Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis. 2008;21:673-681
57.Maher D, Ottensen EA. The global lymphatic filariasis initiative. Trop Doct. 2000;30:179-9
58.Olszewski WL, Manokaran G, Pani S, et al. Bacteriologic studies of skin, tissue lymph, lymph and lymph nodes in patients with filarial lymphedema. Am J Trop Med Hyg. 1997;57:7-15
59.Gandhi GM, Shanker S. Thyroid lymphography. Am J Surg. 1976;131:563-565
60.Hoerauf A, Buttner DW, Adjei O, et al. Onchocerciasis. Clinical review. BJM. 2003;326:207-210
61.Plaisier AP, Van Oortmarssen GJ, Remme J, et al. The reproductive lifespan of Onchocerca volvulus in west African savanna. Acta Trop. 1991; 48:271-284
62.Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg. 1985;34:529-536
63.Hoerauf A, Mand S,Adjei O, et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. 2001;357:1415-1416
64.Lehman JS Jr, Smith FZ, Bassily JH et al. Urinary Schistosomiasis in Egypt: clinical, radiological, bacteriological and parasitological correlations. Am J Trop Med Hyg. 1973; 67(3): 384-399